Shares of Axovant Sciences Ltd (NASDAQ:AXON) have been given a consensus rating of “Hold” by the eight brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $3.81.
AXON has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Tuesday, October 9th. BidaskClub upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 16th. ValuEngine upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Cowen reiterated a “hold” rating on shares of Axovant Sciences in a research note on Thursday, September 20th. Finally, Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 11th.
AXON opened at $1.11 on Friday. The company has a market capitalization of $139.40 million, a P/E ratio of -0.54 and a beta of 1.22. Axovant Sciences has a 12 month low of $0.93 and a 12 month high of $6.59. The company has a quick ratio of 1.97, a current ratio of 1.97 and a debt-to-equity ratio of 1.68.
In related news, major shareholder Svf Investments (Uk) Ltd acquired 10,000,000 shares of the stock in a transaction dated Tuesday, December 18th. The shares were purchased at an average price of $1.00 per share, for a total transaction of $10,000,000.00. Following the transaction, the insider now owns 99,285,714 shares in the company, valued at approximately $99,285,714. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.00% of the company’s stock.
A number of large investors have recently modified their holdings of AXON. Tower Research Capital LLC TRC raised its position in Axovant Sciences by 1,627.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 58,541 shares during the period. GSA Capital Partners LLP purchased a new position in Axovant Sciences in the 2nd quarter worth $338,000. Paloma Partners Management Co purchased a new position in Axovant Sciences in the 2nd quarter worth $356,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Axovant Sciences by 12.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock worth $1,354,000 after purchasing an additional 64,152 shares during the period. Finally, BlackRock Inc. raised its position in Axovant Sciences by 13.5% in the 3rd quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock worth $3,447,000 after purchasing an additional 169,918 shares during the period. Institutional investors own 7.71% of the company’s stock.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Read More: What are retained earnings?
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.